uep_logo
Strada delle Scotte, 6 53100 Siena
tel 0577 233228
info@insostanza.it

Sei in: InSostanza > Esami tossicologici > La buprenorfina (Subutex, Subxone) nelle urine

La buprenorfina (Subutex, Subxone) nelle urine

La buprenorfina, principio attivo delle specialitA� Subutex e Subxone, A? rilevabile nelleA�urine entro 24 ore dal suo utilizzo, in dipendenza comunque, come per ogni altraA�sostanza, dalla quantitA� utilizzata, dalla diuresi, dalle caratteristiche della��individuo, dalA�metabolismo.

Per la sua determinazione possono essere usate comuni metodologie analitiche il cuiA�limite A? nel costo ovvero nella quantitA� di campioni da esaminare. Un kit sufficiente perA�circa 100 campioni ha un costo attorno a 1000 euro per cui A? dispendiosa la��analisi perA�uno o pochi campioni.
Vi A? inoltre il limite che la concentrazione della buprenorfina nelle urine A? cosA� bassa cheA�spesso sfugge a tali analisi, non sufficientemente sensibili, e ne risultano falsi negativi.

Per una certa e perfetta esecuzione della��esame ci si avvale della LCMS o liquido massaA�che consente il diretto rilievo della buprenorfina.
Ogni singola determinazione ha il costo di circa 100 euro.

Dott. Agostino Pasqualini
U.O. Tossicologia Forense
UniversitA� degli Studi di Siena.

 

 

 

 

European Drug Report 2018: Trends and Developments.

High availability of drugs across all types. Over 1 million seizures in Europe in 2016. Over 92 million adults in the EU have tried an illicit drug in their lifetime. 1.3 million people received treatment for illicit drugs. Cocaine purity at street level reached its highest level in a decade. Increase in number of cocaine seizures. Increase in cocaine residues in wastewater in 26 of 31 cities between 2015 and 2017. Rise in number of first-time admissions to specialised treatment for problems related to cocaine. Europe is an important market for drugs trafficked in from other regions. But there are worrying signs of increased drug production inside Europe. Cannabis availability and use remain high. Cannabis is involved in 77 % of drug law offences. Rapid emergence of a commercial cannabis market in parts of the Americas. Fewer new psychoactive substances reported for the first time. But there is more evidence of harm. Health harms linked to highly potent new synthetic cannabinoids and synthetic opioids prompted nine risk assessments. Synthetic cannabinoids are the most frequently seized NPS in Europe. Synthetic opioids and particularly fentanyl derivatives are increasingly detected. Fentanyl derivatives — key players in the US opioid crisis — call for concern & vigilance. NPS use and related harms are a new challenge for prison system. Prisons are a critical setting for addressing the healthcare needs of drug users. Online markets appear to be of growing importance. A recent EMCDDA–Europol study identified more than 100 darknet markets. Concerns over unlicensed benzodiazepines sold on the street and online. Increasing number of overdose deaths raises concerns. Renewed focus on the role of take-home naloxone in overdose response strategies. Read more in the European Drug Report 2018: emcdda.europa.eu/edr2018

LE CREAZIONI DI INSOSTANZA